China's Drugmakers Turn to AI Marketing as Anti-Graft Rules Bite

Reuters reports Chinese drugmakers are marketing via medical AI assistants as anti-graft rules tighten. Null Hypothesis has licensed KnowS; Alibaba Health and Yidu Tech proposals remain on the table.